Oslo, April 7, 2010: OptiNose, a leader in nasal drug delivery systems, is pleased to announce the publication in Cephalalgia of results from its Phase II clinical study investigating the efficacy and ...

Tosymra Nasal Spray 10 mg is a Proprietary Acute Migraine Treatment Approved Under the 505(b)2 Pathway Based on Bioequivalence to Imitrex (sumatriptan) Injection 4 mg GlaxoSmithKline Recently Notified ...

Objective: To study the efficacy and practicality of treating headache in professional footballers with intranasal sumatriptan. Results: Thirty eight attacks were analysed. The two hour response ...

Lesions in White Matter, Migraines Treatment of acute migraine with AVP-825, an investigational Breath-Powered Bi-Directional intranasal delivery system containing sumatriptan powder 22mg, resulted in ...

Lannett Company, Inc. (NYSE: LCI) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Sumatriptan Nasal ...

The FDA has approved sumatriptan nasal spray (Tosymra) for the acute treatment of migraine with or without aura in adults. The FDA has approved sumatriptan nasal spray (Tosymra) for the acute ...

Drug major Cipla on Tuesday said it has received final approval from the United States Food and Drug Administration (USFDA) for Sumatriptan Nasal Spray, indicated for the treatment of migraine attacks ...

Sumatriptan has been established as an effective treatment for migraine, but absorption of oral migraine medications is often delayed. In a double-blind, placebo-controlled phase III trial, ...

Tosymra ® (sumatriptan nasal spray) 10mg is indicated and marketed for the acute treatment of migraine in adults CHATHAM, N.J., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp.